Early neurologic response predicts outcomes after anakinra for immune effector cell–associated neurotoxicity syndrome
Emily C. Liang(Fred Hutch Cancer Center), Jordan Gauthier(Seattle Cancer Care Alliance), Brandon Hayes‐Lattin(Oregon Health & Science University), Erik L. Kimble(University of Washington), Bashi Ratterree, Qian Wu(Cancer Research Center), Andrew J. Portuguese(University of Washington), Sanjog Bastola(Oregon Health & Science University), Christy Khouderchah(University of Washington), Jessica Leonard(Oregon Health & Science University), Rachel Bixler, Robert Ahrenkiel(Oregon Health & Science University), Alexandre V. Hirayama(University of Washington), Eva Medvedova(Oregon Health & Science University), Mazyar Shadman(University of Washington), Gabrielle Meyers(Oregon Health & Science University), Smith Kungwankiattichai, Manoj Rai(Oregon Health & Science University), Richard T. Maziarz(Oregon Health & Science University), Jennifer J. Huang(Stanford Medicine), Andy Chen(Stanford University), Xiancheng Wu(Fred Hutch Cancer Center), Jacqueline Trussell, Dwight Macero(University of Washington), Cheryl Stomberg, Amrita Desai, Jenna Voutsinas(Fred Hutch Cancer Center), Ryan Basom(Fred Hutch Cancer Center), Yang Qiao(Fred Hutch Cancer Center), Rebecca Silbermann(Oregon Health & Science University), Staci Williamson(Oregon Health & Science University), Stephen E. Spurgeon(Oregon Health & Science University), Chi Phan(Oregon Health & Science University), Tanaya Shree(Memorial Sloan Kettering Cancer Center), Craig Okada(Oregon Health & Science University), Yein Jeon(University of Washington)
Cited by 0
Related Papers
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion
|Genes & Development|2010|744
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
|Journal of Clinical Oncology|2017|664
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532